

OHMR Research Ethics and Governance Metrics Program



Metrics Activity Report for NSW PHOs

Reporting Period: Quarter 3 2024
01/07/2024 – 30/09/2024

NSW Office for Health and Medical Research

Executive Summary

This report includes strategic and site level performance and compliance metrics that are collected by the Office for Health and Medical Research (OHMR) from NSW Public Health Organisations (PHOs) on studies authorised during the reporting period. The performance of NSW PHOs on health and medical research are reported four times a year, each covering a 3-month period.

Overall Performance Environment

REGIS is the online platform used to manage ethics and governance applications for all NSW Public Health Organisations. OHMR has undertaken data validation activities with LHD Research Office staff to accurately represent research ethics and governance performance on this platform. These rolling validation activities may result in data reported here to differ from previous reports.

Update to Metrics Program

As reported previously, OHMR implemented the following changes to the Research Key Performance Indicators (KPIs) for inclusion in the Chief Executives' Services Agreement:

- Number of Greater than Low Risk projects (GLR) processed within application total time
 - 90 days for ethics, 60 days for governance
 - Threshold changes
 - >75% = Performing
 - 55%-75% = Underperforming
 - <55% = Not performing



Ethics Review Timelines of Human Research in NSW PHOs

KPI21-03: Ethics Application Approvals - By the Human Research Ethics Committee (HREC) within 90 calendar days

NSW State Benchmark: The benchmark for the 2021/22 financial year onwards is for reviewing human research studies by NSW PHO HRECs within 90 calendar days

Definition:

The proportion of Ethics applications (excluding LNR) approved by the HREC within 90 calendar days, approved within the reporting period.

Context:

The measure will no longer account for clock stops in accordance with the NHMRC Certification Handbook. Instead, the end-to-end time will be measured. Where a valid application is received, the clock starts on the submission closing date for the HREC meeting at which an application will be reviewed. The clock is stopped when the HREC formally notifies the applicant of the final decision.

Desired Outcome:

Ensuring timely processing of ethics approvals for research and clinical trials supports better health outcomes for the people of NSW and maintaining competitiveness through access to the latest treatments from clinical trials.

Selection Criteria Summary:

Scope	Human Research Ethics Applications
Frequency	Quarterly
Inclusions	- Study Type = All - Application Type = Greater than low risk - Approval Type = Approved/ Approved with conditions within the reporting period
Exclusions	- Application Type = Low and negligible risk - Approval Type = Not within the reporting period - Migrated studies
Total	Total time is defined as the measurement of the total, unadjusted time from the Submission Closing Date of the first meeting the application is assigned to, to when the final decision notification email is sent.

Summary for Metric 3









Ethics review performance of NSW HRECs according to the < **90-day benchmark** for studies approved during the reporting period (**Quarter 3 2024**) are shown in **Table 1**.

During the reporting period, 268 studies (greater than low risk pathway) were approved by a NSW Health HREC with an average review time (total time) of 54 days. Of these 268 studies, 99 (37%) were classified as clinical trials (**Table 2**).









Further breakdown of clinical trial approvals by sponsor type is provided in **Table 3** (by NSW PHOs) and **Table 4** (by quarter). Historical performance of NSW PHOs against the old and new benchmarks for the review and approval of human research ethics applications is presented in **Table 5**.

Trends of performance for NSW PHO's **Ethics Approvals within 90 days**



— LHD — NSW



LHD NSW









Overall breakdown and breakdown by NSW LHDs by **Sponsor Types** of Ethics Approvals for reporting period Q3 2024.









Trend of **Average Research Office Days** and **Average Researcher Days** for all GLR Ethics Approval over the reporting period Q2 2022- Q3 2024





Research Office Researcher



Research Office Researcher



Research Office Researcher





Site-specific Assessment (SSA) Authorisation Timelines of Human Research Projects in NSW PHOs

KPI21-04: Research Governance Application Authorisations – SSA Authorisations within 60 calendar days

NSW State Benchmark: The benchmark for the 2021/22 financial year onwards for authorisation of SSA applications is 60 calendar days

Definition:

The proportion of site-specific assessment (SSA) applications (excluding lower to negligible risk) authorised by the Research Governance Office (RGO) within 60 calendar days, authorised within the reporting period.

Context:

The measure will no longer account for clock stops in accordance with the National Health and Medical Research Council Certification. Handbook. Instead, the end-to-end time will be measured. The SSA application received date is the date the RGO or designee receives an SSA application from a researcher regardless of whether it is complete and/or deemed valid. The clock is stopped when the final SSA decision letter is provided to the site principal investigator.

Desired Outcome:

Ensuring timely processing of site approvals for research and clinical trials supports better health outcomes for the people of NSW and maintaining competitiveness through access to the latest treatments from clinical trials.

Selection Criteria Summary:

Scope

Site-specific assessment (SSA) applications

Frequency

Quarterly

Inclusions

- Study Type = All
- Application Type = Greater than low risk
- Approval Type = “Authorised” or “authorised with conditions” within the reporting period

Exclusions

- Application Type = Low and negligible risk
- Migrated studies

Total Time:

Total time is the measurement of the total, unadjusted time from the Submission Date to when the final decision notification email is sent granting approval.

Summary:

SSA review performance of NSW PHOs according to the **<60-day benchmark** for studies authorised during the reporting period (**Quarter 3 2024**) are shown in **Table 6**. During the reporting period,


505 studies (greater than low risk pathway) were authorised in NSW PHOs with an average review time (total time) of **47** days.

Of these **505** studies, **270** were classified as clinical trials (**Table 7**).

Further breakdown of clinical trial SSA authorisations by sponsor type is provided in **Table 8** (by NSW PHOs) and **Table 9** (by quarter). Historical performance of NSW PHOs against the old and new benchmarks for the review and authorisation of governance applications is presented in **Table 10**.


Trends of performance for NSW PHO's SSA Authorisations within 60 days

— LHD — NSW




— LHD — NSW


MNCLHD




NBMLHD




NNSWLHD




NSLHD




NSWPTH




SCHN



SESLHD




SLHD-CCD




— LHD — NSW


SLHD-RPA




SNSWLHD




SVHN




SWSLHD





WNSWLHD



WSLHD




Overall breakdown and breakdown by LHDs of SSA Authorisations by **Sponsor Types** for reporting period Q3 2024.










Trend of **Average Research Office days** and **Average Researcher days** for all GLR SSAs Authorisations by LHD over reporting period Q2 2022 - Q3 2024







— Research Office — Researcher




Research Office Researcher




Research Office Researcher




Average total time (days) for Clinical Trials Authorisation by Sponsor Type trends between Q4 2021 and Q3 2024




Average research office time (DAYS) for Clinical Trial Authorisation by Sponsor type trends between Q4 2021 and Q3 2024




Breakdown of **Sponsor Type** of all GLR **SSA Authorisations** by Site




Breakdown of **Sponsor Type** of all GLR **SSA Authorisations** by Site



Breakdown of **Study Types** for all GLR **SSA Authorisations** by Site



Breakdown of **Study Types** for all GLR **SSA Authorisations** by Site



OHMR Research Ethics
and Governance Metrics
Program
Appendix 1



Metrics Activity Report for NSW PHOs

Reporting Period: Quarter 3 2024
01/07/2024 – 30/09/2024

NSW Office for Health and Medical Research



Table 1. The **90 calendar days benchmark** for approval of human research ethics applications (**greater than low risk**) during the reporting period.

NSW PHOs	Ethics Approval (Q3 2024)					
	All greater than low risk applications					
	Total Number of Applications	Total Time 90 Day Benchmark			Total Time Breakdown (calendar days)	
		Count < 90 Day Benchmark	% < 90 Day Total Time Benchmark	Average Total Time (Days)	Average Research Office Time	Average Researcher Time
BLLBRRY	39	36	92%	50	25	26
CINSW	7	6	86%	67	37	31
HNELHD	21	21	100%	27	19	8
ISLHD	0	0	-	-	-	-
JHFMHN	2	1	50%	89	63	26
NBMLHD	4	4	100%	53	35	19
NNSWLHD	1	0	0%	92	73	19
NSLHD	36	36	100%	27	14	14
SCHN	15	14	93%	63	41	22
SESLHD	23	18	78%	80	55	25
SLHD-CCD	9	9	100%	44	23	22
SLHD-RPA	38	36	95%	50	24	26
SVHN	21	17	81%	62	28	34
SWSLHD	24	18	75%	65	43	22
WNSWLHD	3	2	67%	90	62	28
WSLHD	25	18	72%	80	38	42
TOTAL	268	236	88%	54	33	20

Table 2. The 90 calendar days benchmark for the approval of clinical trials (greater than low risk) during the reporting period.

NSW PHOs	Ethics Approval (Q3 2024)					
	Clinical Trials					
	Total Number of Applications	Total Time 90 Day Benchmark			Total Time Breakdown (calendar days)	
		Count < 90 Day Benchmark	% < 90 Day Total Time Benchmark	Average Total Time (Days)	Average Research Office Time	Average Researcher Time
BLLBRRY	39	36	92%	50	25	26
CINSW	0	0	-	-	-	-
HNELHD	9	9	100%	29	19	10
ISLHD	0	0	-	-	-	-
JHFMHN	0	0	-	-	-	-
NBMLHD	2	2	100%	66	42	25
NNSWLHD	0	0	-	-	-	-
NSLHD	5	5	100%	50	22	28
SCHN	6	6	100%	61	42	20
SESLHD	4	1	25%	113	73	39
SLHD-CCD	0	0	-	-	-	-
SLHD-RPA	10	8	80%	74	41	33
SVHN	5	5	100%	54	26	28
SWSLHD	9	7	78%	65	36	29
WNSWLHD	0	0	-	-	-	-
WSLHD	12	9	75%	76	36	40
TOTAL	99	85	86%	59	31	28

Table 3. Breakdown of NSW PHO performances in **clinical trial approvals** (greater than low risk) during the reporting period **by sponsor type**

	Collaborative group			Commercial entity			Investigator-initiated		
NSW PHOs	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)
BLLBRRY	0	-	-	38	24	50	1	37	71
CINSW	0	-	-	0	-	-	0	-	-
HNELHD	2	20	29	2	20	27	4	18	29
ISLHD	0	-	-	0	-	-	0	-	-
JHFMHN	0	-	-	0	-	-	0	-	-
NBMLHD	0	-	-	0	-	-	2	42	66
NNSWLHD	0	-	-	0	-	-	0	-	-
NSLHD	0	-	-	1	12	38	4	25	54
SCHN	0	-	-	1	33	42	5	43	65
SESLHD	0	-	-	1	77	90	3	72	120
SLHD-CCD	0	-	-	0	-	-	0	-	-
SLHD-RPA	6	42	78	2	32	60	2	46	75
SVHN	1	23	58	2	27	56	2	27	51
SWSLHD	0	-	-	5	43	83	4	28	44
WNSWLHD	0	-	-	0	-	-	0	-	-
WSLHD	1	51	119	9	33	60	2	42	128
Grand Total	10	36	70	61	28	54	29	37	66

Table 4. Quarterly **clinical trial approvals** (greater than low risk) in the last 3 reporting period (between 01/01/2024 and 30/09/2024), **by sponsor type**

	Q1 2024			Q2 2024			Q3 2024		
Sponsor Type	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)
Collaborative Group	10	48	77	14	28	61	10	36	70
Commercial Entity	46	32	59	56	31	55	61	28	54
Investigator Initiated	28	31	57	28	30	67	29	37	66
Total	85	26	43	98	30	61	100	34	63

Table 5. Historical performance of NSW PHOs against **the old and new benchmarks** for the review and approval of human research ethics applications (greater than low risk) in the last 3 reporting period (between 01/01/2024 and 30/09/2024).

NSW PHOs		Q1 2024							Q2 2024							Q3 2024						
		Total Number of Applications	45 Day Benchmark (with clock)			90 Day Benchmark (without clock)			Total Number of Applications	45 Day Benchmark (with clock)			90 Day Benchmark (without clock)			Total Number of Applications	45 Day Benchmark (with clock)			90 Day Benchmark (without clock)		
			Count 45 Day Benchmark	% 45 Day Benchmark	Average Research Office Time (Days)	Count 90 Day Benchmark	% 90 Day Total Time Benchmark	Average Total Time (Days)		Count 45 Day Benchmark	% 45 Day Benchmark	Average Research Office Time (Days)	Count 90 Day Benchmark	% 90 Day Total Time Benchmark	Average Total Time (Days)		Count 45 Day Benchmark	% 45 Day Benchmark	Average Research Office Time (Days)	Count 90 Day Benchmark	% 90 Day Total Time Benchmark	Average Total Time (Days)
BLLBRRY	29	23	79%	23	26	90%	50	33	30	91%	21	30	91%	46	39	34	87%	26	36	92%	50	
CINSW	3	1	33%	66	0	0%	101	7	5	71%	57	5	71%	103	7	5	71%	31	6	86%	67	
HNELHD	14	14	100%	8	14	100%	28	23	23	100%	12	23	100%	28	21	21	100%	8	21	100%	27	
ISLHD	0	0	0%	0	0	0%	0	0	0	-	-	0	-	-	0	0	-	-	0	-	-	
JHFMHN	3	0	0%	75	3	100%	75	0	0	-	-	0	-	-	2	2	100%	26	1	50%	89	
NBMLHD	2	1	50%	24	2	100%	49	3	3	100%	12	3	100%	59	4	4	100%	19	4	100%	53	
NNSWLHD	3	2	67%	64	1	33%	116	3	1	33%	126	1	33%	195	1	1	100%	19	0	0%	92	
NSLHD	30	27	90%	18	30	100%	32	33	30	91%	17	33	100%	30	36	33	92%	14	36	100%	27	
SCHN	12	8	67%	34	9	75%	60	19	10	53%	57	10	53%	99	15	14	93%	22	14	93%	63	
SESLHD	15	12	80%	28	10	67%	81	13	12	92%	21	12	92%	63	23	19	83%	25	18	78%	80	
SLHD-CCD	8	4	50%	41	8	100%	67	8	6	75%	38	8	100%	62	9	8	89%	22	9	100%	44	
SLHD-RPA	26	23	88%	23	26	100%	54	35	30	86%	29	34	97%	52	38	33	87%	26	36	95%	50	
SVHN	16	12	75%	31	12	81%	69	21	11	52%	45	13	62%	82	21	15	71%	34	17	81%	62	
SWSLHD	15	12	80%	36	8	53%	111	18	16	89%	23	12	67%	90	24	20	83%	22	18	75%	65	
WNSWLHD	9	6	67%	39	6	67%	74	8	6	75%	27	7	88%	55	3	2	67%	28	2	67%	90	
WSLHD	24	13	54%	45	13	54%	85	21	15	71%	32	16	76%	75	25	16	64%	42	18	72%	80	
TOTAL	209	158	76%	21	169	88%	54	245	198	81%	21	207	80%	54	268	227	85%	21	236	80%	54	

Table 6: The 60 calendar days benchmark for authorisation of governance applications (greater than low risk) during the reporting period.

NSW PHOs	SSA Approvals (Q3 2024)							
	All greater than low risk applications							
		60 Day Benchmark (without clock)			Total Time Breakdown (calendar days)			
	Total Number of Applications	Count of < 60 Day Benchmark	% < 60 Day Total Time Benchmark	Average Total Time (Days)	Average Research Office Time	Average Head of Dept Time	Average Chief Exec Time	Average Researcher Time
ASNSW	1	1	100%	28	16	6	4	2
Calvary	22	20	91%	27	18	1	2	6
CCLHD	7	7	100%	19	10	3	0	6
FWLHD	0	0	-	-	-	-	-	-
HNELHD	39	38	97%	24	4	5	3	11
ISLHD	13	12	92%	32	7	21	0	3
JHFMHN	2	2	100%	17	7	4	3	3
MLHD	4	3	75%	40	20	8	1	11
MNCLHD	6	5	83%	37	13	3	6	15
NBMLHD	10	9	90%	54	23	11	2	17
NNSWLHD	1	1	100%	46	0	0	4	42
NSLHD	58	52	90%	31	7	6	4	15
NSWHPTH	13	6	46%	92	25	35	0	33
SCHN	34	15	44%	84	25	22	0	37
SESLHD	40	40	100%	41	15	11	0	16
SLHD-CCD	26	24	92%	37	7	6	2	22
SLHD-RPA	62	54	87%	29	6	7	7	9
SNSWLHD	1	1	100%	8	0	1	4	3
SVHN	23	18	78%	54	10	15	2	27
SWSLHD	71	39	55%	86	24	18	0	44
WNSWLHD	4	4	100%	38	13	9	0	16
WSLHD	68	57	84%	41	5	8	2	26
TOTAL	505	409	81%	47	12	11	2	22

Table 7: The 60 calendar days benchmark for the authorisation of clinical trials (greater than low risk) during the reporting period.

NSW PHOs	SSA Approvals (Q3 2024) Clinical Trials							
	Total Number of Applications	60 Day Benchmark (without clock)			Total Time Breakdown (calendar days)			
		Count of < 60 Day Benchmark	% < 60 Day Total Time Benchmark	Average Total Time (Days)	Average Research Office Time	Average Head of Dept Time	Average Chief Exec Time	Average Researcher Time
ASNSW	0	0	-	-	-	-	-	-
CALVARY	20	19	95%	25	15	1	2	6
CCLHD	3	3	100%	11	5	4	0	2
FWLHD	0	0	-	-	-	-	-	-
HNELHD	15	15	100%	29	6	5	6	12
ISLHD	10	10	100%	19	5	9	0	4
JHFMHN	0	0	-	-	-	-	-	-
MLHD	2	1	50%	47	26	4	2	15
MNCLHD	4	4	100%	26	9	4	6	7
NBMLHD	6	6	100%	54	30	15	2	7
NNSWLHD	0	0	-	-	-	-	-	-
NSLHD	19	19	100%	20	7	4	3	6
NSWHPH	1	0	0	255	13	184	0	58
SCHN	15	8	53%	59	22	14	0	22
SESLHD	23	23	100%	41	14	13	0	14
SLHD-CCD	15	14	93%	40	10	8	4	18
SLHD-RPA	31	25	81%	40	7	11	11	11
SNSWLHD	0	0	-	-	-	-	-	-
SVHN	15	13	87%	50	11	11	2	26
SWSLHD	41	21	51%	96	25	26	0	45
WNSWLHD	3	3	100%	33	13	11	0	9
WSLHD	47	42	89%	25	5	7	2	12
TOTAL	270	226	84%	44	12	12	3	17

Table 8. NSW PHO performances in clinical trial authorisations (greater than low risk) during the reporting period, by sponsor type.

	Collaborative group			Commercial entity			Investigator-initiated		
NSW PHOs	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)
ASNSW	0	-	-	0	-	-	0	-	-
CALVARY	4	7	30	14	13	19	2	45	60
CCLHD	1	3	4	2	7	15	0	-	-
FWLHD	0	-	-	0	-	-	0	-	-
HNELHD	7	8	37	1	3	23	7	4	22
ISLHD	1	15	43	7	3	15	2	8	20
JHFMHN	0	-	-	0	-	-	0	-	-
MLHD	1	28	62	0	-	-	1	24	32
MNCLHD	3	8	29	1	13	16	0	-	-
NBMLHD	1	14	42	2	37	57	3	30	57
NNSWLHD	0	-	-	0	-	-	0	-	-
NSLHD	6	8	20	7	6	16	6	9	26
NSWHPH	0	-	-	0	-	-	0	-	-
SCHN	2	29	71	8	24	46	5	17	75
SESLHD	11	12	46	11	15	35	1	37	54
SLHD-CCD	4	31	77	9	2	19	2	4	58
SLHD-RPA	3	25	64	18	4	29	10	7	52
SNSWLHD	0	-	-	0	-	-	0	-	-
SVHN	1	11	189	11	7	27	3	24	88
SWSLHD	8	48	121	18	14	37	15	26	154
WNSWLHD	0	-	-	0	-	-	3	13	33
WSLHD	2	3	13	36	4	19	9	6	55
Total	55	18	56	145	9	26	64	15	74

Table 9. Quarterly clinical trial authorisations (greater than low risk applications) approved during the last 3 reporting period, by sponsor type

	Q1 2024			Q2 2024			Q3 2024		
Sponsor Type	Total # of Applications	Average Research Office	Average Total Time	Total # of Applications	Average Research Office	Average Total Time	Total # of Applications	Average Research Office	Average Total Time
Collaborative Group	48	28	63	63	16	51	55	18	56
Commercial Entity	105	20	42	141	11	30	145	9	26
Investigator Initiated	40	20	60	56	25	94	64	15	74
Total	193	22	47	260	15	47	264	14	52

Table 10. Historical performance of NSW PHOs against the old and new benchmarks for the review and authorisation of SSA applications (greater than low risk) for the last 3 reporting periods (between 01/01/2024 and 30/09/2024).

	Q1 2024							Q2 2024							Q3 2024						
LHD	Number of Applications	15 Day Benchmark (with clock)			60 Day Benchmark (without clock)			Number of Applications	15 Day Benchmark (without clock)			60 Day Benchmark (without clock)			Number of Applications	15 Day Benchmark (with clock)			60 Day Benchmark (without clock)		
		Count of 15 Day Benchmark	% 15 Day Benchmark	Average RO Time (Days)	Count of 60 Day Benchmark	% 60 Day Total Time Benchmark	Average Total Time (Days)		Count of 15 Day Benchmark	% 15 Day Benchmark	Average RO Time (Days)	Count of 60 Day Benchmark	% 60 Day Total Time Benchmark	Average Total Time (Days)		Count of 15 Day Benchmark	% 15 Day Benchmark	Average RO Time (Days)	Count of 60 Day Benchmark	% 60 Day Total Time Benchmark	Average Total Time (Days)
ASNSW	1	1	1	14	1	100%	18	1	1	1	0	0	0%	234	1	0	0	16	1	100%	28
CALVARY	9	8	89%	10	9	100%	12	9	4	44%	13	9	100%	16	22	12	55%	18	20	91%	27
CCLHD	7	6	86%	9	7	100%	33	12	10	83%	5	10	83%	49	7	5	71%	10	7	100%	19
FWLHD	0	0	0%	0	0	0%	0	0	0	-	-	0	-	-	0	0	-	-	0	-	-
HNELHD	22	18	82%	10	20	91%	25	34	28	82%	9	34	100%	25	39	37	95%	4	38	97%	24
ISLHD	4	4	100%	3	4	100%	8	19	18	95%	3	16	84%	24	13	11	85%	7	12	92%	32
JHFMHN	0	0	0%	0	0	0%	0	2	2	1	4	1	50%	45	2	2	1	7	2	100%	17
MLHD	2	2	100%	11	2	100%	21	8	8	100%	2	8	100%	30	4	1	25%	20	3	75%	40
MNCLHD	9	6	67%	9	9	100%	30	9	7	78%	10	8	89%	43	6	3	50%	13	5	83%	37
NBMLHD	6	2	33%	28	4	67%	77	9	2	22%	37	5	56%	68	10	5	50%	23	9	90%	54
NNSWLHD	2	1	50%	14	2	100%	57	0	0	-	-	0	-	-	1	1	100%	0	1	100%	46
NSLHD	48	26	54%	18	46	96%	39	52	38	73%	10	49	94%	34	58	51	88%	7	52	90%	31
NSWHPH	7	2	29%	40	0	0%	132	9	2	22%	34	1	11%	141	13	6	46%	25	6	46%	92
SCHN	6	2	33%	21	3	50%	67	46	27	59%	15	34	74%	52	34	10	29%	25	15	44%	84
SESLHD	43	36	84%	9	38	88%	42	57	34	60%	12	54	95%	37	40	24	60%	15	40	100%	41
SLHD-CCD	18	12	67%	9	18	100%	26	28	25	89%	5	28	100%	19	26	25	96%	7	24	92%	37
SLHD-RPA	50	33	66%	13	49	98%	32	57	48	84%	5	57	100%	25	62	54	87%	6	54	87%	29
SNSWLHD	2	0	0%	165	0	0%	165	6	2	33%	23	4	67%	301	1	1	100%	0	1	100%	8
SVHN	22	18	82%	11	16	73%	54	42	32	76%	10	31	74%	48	23	18	78%	10	18	78%	54
SWSLHD	48	4	8%	55	9	19%	102	133	92	69%	15	97	73%	51	71	44	62%	24	39	55%	86
WNSWLHD	5	4	80%	9	3	60%	48	12	12	100%	5	11	92%	23	4	4	100%	13	4	100%	38
WSLHD	65	48	74%	12	45	69%	50	31	27	87%	9	23	74%	42	68	66	97%	5	57	84%	41
Total	376	233	62%	20	286	76%	51	576	419	73%	13	486	84%	45	505	380	75%	12	409	81%	47

A list of NSW PHOs names and abbreviations that review and/or authorise human research studies:

Human Research Ethics Committee/ Research Governance Office Names	Abbreviation used in the tables	Ethics	Site
Ambulance Service of NSW	ASNSW		Yes
Bellberry	BLLBRRY	Yes	
Calvary Mater Hospital Newcastle	CALVARY		Yes
Central Coast LHD	CCLHD		Yes
NSW Population & Health Services Research Ethics Committee	CINSW	Yes	
Greater Western LHD	WNSWLHD	Yes	Yes
Hammond Care	HCARE		Yes
Hunter New England LHD	HNELHD	Yes	Yes
Justice Health & Forensic Mental Health Network	JHFMHN	Yes	Yes
Mid North Coast LHD	MNCLHD		Yes
Murrumbidgee LHD	MLHD		Yes
Northern NSW LHD	NNSWLHD	Yes	Yes
Nepean Blue Mountains LHD	NBMLHD	Yes	Yes
Northern Sydney LHD	NSLHD	Yes	Yes
NSW Health Pathology	NSWHPTH		Yes
Royal Rehabilitation Centre Sydney HREC	RRCS	Yes	
Sydney Children's Hospitals Network	SCHN	Yes	Yes
South Eastern Sydney LHD	SESLHD	Yes	Yes
Sydney LHD (Concord Zone)	SLHD – CCD	Yes	Yes
Sydney LHD (RPAH Zone)	SLHD – RPA	Yes	Yes
Southern NSW LHD	SNSWLHD		Yes
St Vincent's Hospital	SVHN	Yes	Yes
South Western Sydney LHD	SWSLHD	Yes	Yes
Illawarra Shoalhaven LHD (joint committee with University of Wollongong)	ISLHD	Yes	Yes
Western Sydney LHD	WSLHD	Yes	Yes



For more information

This report has been prepared by the Research Ethics and Governance Unit in Office for Health and Medical Research.

For further enquiries and for the use of this report please contact:

James Cokayne

Principal Policy Officer

Research Ethics and Governance Unit

Office for Health and Medical Research

[Tel \(02\) 9391 9920](tel:0293919920) | james.cokayne@health.nsw.gov.au

Yagiz Aksoy

Senior Policy Officer

Research Ethics and Governance Unit

Office for Health and Medical Research

[Tel \(02\) 9461 7887](tel:0294617887) | yagiz.aksoy@health.nsw.gov.au

Deb Aldridge

Policy Officer and Data Analyst

Research Ethics and Governance Unit

Office for Health and Medical Research

[Tel \(02\) 93919854](tel:0293919854) | deborah.aldridge@health.nsw.gov.au